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Abstract
Background: Greater age and body mass index are strong risk factors for osteoarthritis (OA). Older and overweight
individuals may be more susceptible to OA because these factors alter tissue turnover in menisci, articular cartilage,
and bone via altered glucose homeostasis and inflammation. Understanding the role of inflammation and glucose
homeostasis on structural features of early-stage OA may help identify therapeutic targets to delay or prevent the
onset of OA among subsets of adults with these features. We examined if serum concentrations of glucose homeostasis
(glucose, glycated serum protein [GSP]) or inflammation (C-reactive protein [CRP]) were associated with prevalent knee
bone marrow lesions (BMLs) or effusion among adults without knee OA.
Methods: We conducted a cross-sectional study using baseline data from the Osteoarthritis Initiative. We selected
participants who had no radiographic knee OA but were at high risk for knee OA. Blinded staff conducted assays for
CRP, GSP, and glucose. Readers segmented BML volume and effusion using semi-automated programs. Our outcomes
were prevalent BML (knee with a BML volume > 1 cm3) and effusion (knee with an effusion volume > 7.5 cm3). We
used logistic regression models with CRP, GSP, or glucose concentrations as the predictors. We adjusted for
age, sex, body mass index (BMI), and Physical Activity Scale for the Elderly (PASE) scores.
Results: We included 343 participants: mean age = 59 ± 9 years, BMI = 27.9 ± 4.5 kg/m2, PASE score = 171 ± 82,
and 64% female. Only CRP was associated with BML prevalence (odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.
09 to 1.87). For effusion, we found an interaction between BMI and CRP: only among adults with a BMI <25 kg/m2 was
there a significant trend towards a positive association between CRP and effusion (OR = 1.40, 95% CI = 1.00 to 1.97). We
detected a U-shaped relationship between GSP and effusion prevalence. Fasting glucose levels were not significantly
associated with the presence of baseline effusion or BML.
Conclusions: Among individuals without knee OA, CRP may be related to the presence of BMLs and effusion among
normal weight individuals. Abnormal GSP may be associated with effusion. Future studies should explore whether
inflammation and glucose homeostasis are predictive of symptomatic knee OA.
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Background
Greater age and body mass index are strong risk factors
for osteoarthritis (OA) [1–4]. Older and overweight indi-
viduals may be more susceptible to OA because these
factors alter tissue turnover in menisci, articular cartil-
age, and bone via altered glucose homeostasis [5–9] and
inflammation [8, 10–14]. Individuals with osteoarthritis
(OA) have greater systemic inflammation [15] and im-
paired glucose homeostasis [16]. However, it remains
unclear if systemic inflammation and glucose homeosta-
sis relate to specific structural features of early-stage
OA, namely bone marrow lesions (BMLs) and effusion.
BMLs and effusion are common features of OA that are
associated with incidence of disease and symptoms [17–
20]. Specifically, BMLs may reflect changes in the sub-
chondral bone (e.g., fibrosis, edema, necrosis, abnormal
trabeculae) that may predispose the joint to articular
cartilage loss and greater knee pain [17]. Meanwhile, ef-
fusion and synovitis are linked to incident radiographic
knee OA up to 2 years prior to diagnosis [19]. BMLs
and effusion are particularly interesting because they can
change size in less than 12 weeks [21, 22]. Furthermore,
clinical interventions may reduce BML size [23, 24] and
effusion volume [22].
Understanding the role of inflammation and glucose
homeostasis on structural features of early-stage OA
may help identify therapeutic targets to delay or prevent
the onset of OA among subsets of adults with these
features. C-reactive protein (CRP) is a common clinical
biomarker used to test systemic inflammation [25]. Indi-
viduals with greater CRP concentration are more likely
to have greater OA-related symptoms [26] and develop
incident radiographic OA [27]. In relation to specific
structural features of knee OA, one study found that
CRP may be associated with BMLs among adults with
knee OA [28] but other investigators reported null find-
ings among individuals with and without OA [29].
Hence, we evaluated CRP because it may play a role in
OA pathophysiology, the biomarker is clinically avail-
able, and prior studies assessed CRP in relation to OA.
Despite evidence that metabolic syndrome and
diabetes may be associated with OA there is limited evi-
dence about the role of glucose homeostasis on BMLs or
effusion [30]. To assess altered glucose homeostasis, we
assessed glucose concentrations, which offers an assess-
ment of glucose levels at the time of the study visit, and
glycated serum protein (GSP), which provides a stable
marker of glucose homeostasis over the 2 to 3 weeks
prior to the study visit. It would be valuable to further
explore the association between inflammation and glu-
cose homeostasis among individuals without knee OA.
We sought to expand prior research by examining
only individuals without radiographic knee OA. We
assessed CRP and glucose concentrations, which had
been tested in prior studies, and GSP, which provides a
stable indicator of glucose homeostasis. The purpose of
this study was to determine if serum concentrations of
impaired glucose homeostasis (glucose or GSP) or sys-
temic inflammation (CRP) were associated with the
prevalence of knee BMLs or effusion. We focused on
serum concentrations of these measures because serum
would be easier to collect in most clinical settings than
other samples (e.g., synovial fluid). Our long-term goal is
to understand the relationship between glucose and/or
inflammatory impairment and BMLs or effusion. This
study represents a key early step to understanding
whether systemic inflammation or irregular glucose
homeostasis predisposes a knee to BMLs or effusion or
whether BMLs and effusion lead to systemic inflamma-
tion and glucose irregularity.
Methods
The Osteoarthritis Initiative (OAI) is a longitudinal,
multi-center, observational study of 4796 individuals
with or at risk for knee OA at four sites in the United
States: Memorial Hospital of Rhode Island, The Ohio
State University, University of Maryland and Johns
Hopkins University, and the University of Pittsburgh.
The study staff enrolled men and women (45 to 79 years
of age) between February 2004 and May 2006. Descrip-
tions of the eligibility criteria and the OAI protocol are
publicly available on the OAI website [31]. The OAI
study was approved by institutional review boards at
each OAI clinical site and the coordinating center:
Memorial Hospital of Rhode Island Institutional Review
Board, The Ohio State University’s Biomedical Sciences
Institutional Review Board, University of Pittsburgh
Institutional Review Board, University of Maryland
Baltimore – Institutional Review Board, and Committee
on Human Research at University of California, San
Francisco. All participants provided informed consent.
To determine if serum concentrations of impaired glu-
cose homeostasis (glucose or GSP) or systemic inflam-
mation (CRP) were associated with the prevalence of
knee BMLs or effusion, we conducted a secondary ana-
lysis among a well characterized case-control sample
that included three groups (n = 125/group): development
of accelerated knee OA (case), common knee OA, or no
knee OA (Fig. 1) [32–34]. One-hundred and twenty-five
knees had no radiographic OA (Kellgren-Lawrence [KL]
grade < 2) at the OAI baseline but then developed
advanced-stage knee OA (KL grade 3 or 4) within
4 years. Knees from the other 2 groups were randomly
matched by sex to the cases in a 1:1 ratio. Common
knee OA was defined as no radiographic knee OA at
baseline and progressed in KL grade ≥ 1 but did not
reach advanced-stage knee OA over the course of 4 years.
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No knee OA was defined as no radiographic knee OA at
baseline and had no change in KL grade between the
baseline visit and 4 years thereafter. From the 3 groups
(n = 375), we included 343 individuals who had sagittal
intermediate-weighted, turbo spin echo, fat-suppressed
magnetic resonance (MR) images and fasting serum data
available at baseline (accelerated knee OA: n = 99, com-
mon knee OA: n = 119, no knee OA: n = 125). This sam-
ple of participants offered us the advantage of a rich
dataset and enabled us to ensure an adequate sample
size of knees had baseline BMLs and effusion.
We included one knee per person. Among those who
progressed over the subsequent 4 years, we included the
knee with the greatest radiographic progression. For in-
dividuals with no radiographic progression, we selected
a knee to match one person of the same sex who
developed advanced-stage radiographic knee OA.
MR image acquisition
To assess BMLs and knee effusion volume we used
sagittal intermediate-weighted, turbo spin echo, fat-
suppressed MR images which were acquired at the OAI
baseline visit (field of view = 160 mm, slice thickness =
3 mm, skip = 0 mm, flip angle = 180 degrees, echo time
= 30 ms, recovery time = 3200 ms, 313 × 448 matrix
(interpolated to 512 × 512), phase encode superior/infer-
ior, × resolution = 0.357 mm, and y resolution =
0.511 mm) [35]. All MR sequences were taken using one
of four identical Siemens Trio 3-Tesla MR systems and a
USA Instruments quadrature transmit-receive knee coil
Fig. 1 Flow chart of eligibility for participants in analyses
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at one of the four OAI clinical sites. The OAI protocol
for MR imaging is available on the OAI website [31].
BML measurements
A single reader (ACS) used a semi-automated program,
which we described previously [36–38], to measure
BMLs in the distal femur and proximal tibia on sagittal
intermediate-weighted, turbo spin echo, fat-suppressed
MR images. First, the reader identified the first and last
slices in the MR sequence in which the tibia or femur
are present. Following this, the reader marked several
points along the articular surface of both the tibia and
femur to define the crude boundaries of each bone. To
mark the border furthest from the articular surface the
reader marked the bone just prior to the epiphyseal line.
Once the reader completed the manual steps, the pro-
gram automatically segmented the bone boundary and
then the areas of high-signal intensity within the bone
by performing a thresholding and curve evolution
process twice. These areas of high-signal intensity repre-
sented a probable BML. We then used two criteria to ex-
clude false-positive regions and to define a BML: (1) the
distance between a BML and the articular surface should
be ≤10 mm [39–41] and (2) a BML should appear on >1
MR image. The program output the BML volume for 4
different regions: medial femur, lateral femur, medial
tibia, and lateral tibia.
Our reader had good reliability (intra-tester ICC 3,1
model baseline BML = 0.86 to 0.97). The reader also had
good reliability compared with previous readers in our
team (inter-tester intraclass correlation coefficient; ICC
2,1 model: baseline BML = 0.75 to 0.93). A second reader
(JBD) reviewed all images for quality control, assuring
that bone segmentation remained consistent across
knees and time.
Effusion measurements
Two readers measured knee effusion volume on sagittal
intermediate-weighted, turbo spin echo, fat-suppressed
MR images using a semi-automated program. Since the
MR images were acquired without contrast the volumet-
ric measurement may have included knee effusion and
synovitis; however, throughout this manuscript we will
describe the outcome as knee effusion volume. The pro-
gram required the reader to first mark the first and last
slice of the MR sequence in which the tibia or femur are
visible. The reader then marked the base of the patella
and the distal attachment of the patellar ligament into
the tibial tuberosity on a middle slice. Following this, the
program automatically applied a threshold to segment
the effusion volume (areas of high-signal intensity)
within the entire knee. The user then reviewed each slice
with the option to manually adjust the threshold or
remove areas of high-signal intensity that were not effu-
sion (e.g., subchondral bone cysts).
Two readers (JBD and FA) used the semi-automated
software to quantify changes in MR-based knee effusion.
Intra-tester reliability was good (ICC 3,1 model): reader
1 (JBD) baseline = 0.96; reader2 [FA] baseline = 0.84).
Since inter-tester reliability was = 0.42, reader 1 con-
ducted a quality review of all segmented images to en-
sure consistent results between readers, knees, and time.
The final data was based on the reviewed segmentation
results that were corrected by reader 1.
Biospecimens collection
Participation in the OAI was contingent upon a baseline
fasting blood draw. Participants were asked to fast for
>8 h prior to their study visit. Trained staff performed
baseline blood draws at least 1 h after the participant
had gotten up in the morning.
Immediately after collection, study staff inverted the
serum sample tubes and kept them at room temperature
for 30 min. Following these 30 min, the tubes were cen-
trifuged at 4 °C for a total of 30,000 g-minutes and then
immediately transferred to cryovials. Within 15 min of
being transferred to cryovials the samples were placed in
a − 70 °C freezer for at least 30 min prior to being
shipped to Fisher Bioservices for long-term storage. In
September 2015, Fisher Bioservices shipped the samples
to Temple University School of Medicine. Additional de-
tails regarding the collection of biospecimens can be
found in the OAI protocols, which are available on the
OAI website [31].
Biospecimens assay
All assays were performed at Temple University School
of Medicine within 2 months of delivery. The samples
were de-identified to ensure the laboratory staff was
blinded. To assess serum high-sensitivity CRP, an
enzyme-linked immunosorbent assay was used (ELISA,
Novex by Life Technology, Carlsbad, CA; range =
18.75–1200 pg/mL, sensitivity = 18.75 pg/mL, coefficient
of variation <7.52% for intra-assay precision, and coeffi-
cient of variation <10% for inter-assay precision). To
assay GSP, an ELISA kit was used (MyBioSource, San
Diego, CA; range = 78.125 μM – 1000 nmol/mL, sensi-
tivity = 48.875 μM/mL, and coefficient of variation
<10%). Samples used for glucose analyses were deprotei-
nized prior to analysis with 10kD Spin Columns
(Abcam, Cambridge, MA), per manufacturer’s directions.
For fasting glucose levels, Glucose Assay Kits were used
(Abcam; range = 1–1000 μM, sensitivity = 1 μM/mL, and
coefficient of variation <2%). All samples were tested in
duplicate.
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Other clinical variables
We extracted potential confounders from the public
OAI data files: age, sex, body mass index (BMI), and
Physical Activity Scale for the Elderly (PASE) scores
(Files: enrollees, version 22; allclinical00, version 0.2.2).
We also extracted self-reported diabetes from the
Charlson Comorbidity Index. All variables were
collected based on standardized procedures, which are
defined in the OAI protocols, which are available on the
OAI website (15).
Statistical analyses
Initially, we calculated descriptive statistics; explored the
distribution of CRP, GSP, and glucose concentrations,
and applied the natural log (ln) transformation for GSP
to stabilize the variable. Since our BML segmentation
program detected small areas of increased signal inten-
sity on every knee, we classified a knee as having a
prevalent BML if any region (medial femur, medial tibia,
lateral femur, lateral tibia) had a BML volume > 1 cm3.
The BML cut-point was based on a prior classification
and regression tree analysis with medial joint space nar-
rowing progression as an outcome [37, 42]. A knee was
classified as having prevalent effusion if the knee effu-
sion volume was greater than the median knee effusion
volume (> 7.5 cm3).
To assess the relationship between serum measure-
ments (predictors) and BMLs or knee effusion
(outcomes) we used logistic regression models, adjusting
for age, sex, BMI, and PASE score. In separate models,
we explored interactions between the biomarkers and
BMI. We checked for a linear relationship between the
three predictors and the log odds for the presence of
BMLs or effusion using a plot spline transformation with
linear hypothesis test (SAS macro: %PSPLINET, 3
knots). When a nonlinear relationship was present we
performed piece-wise logistic regression analyses and se-
lected the cut-point based on spline graphs.
We conducted 2 sensitivity analyses: 1) adjusting for
self-reported smoking ever in life and 2) only including
people who reported no diabetes. We also explored if
there was an interaction between sex and any of the
three serum measurements.
All analyses were performed with SAS Enterprise
Guide 7.13 (Cary, NC).
Results
We had complete data for 343 participants. The cohort
had a mean age of 59 ± 9 years, BMI of 27.9 ± 4.4 kg/m2,
PASE score of 171 ± 82, and 64% were female. Only 10
participants reported diabetes on the Charlson
Comorbidity Index (7 had missing data). Overall, the
sample had a mean (standard deviation) total BML
volume 0.92 (1.48) cm3, effusion volume 9.09 (6.28) cm3,
CRP 3.31 (1.21) mg/L, lnGSP 5.48 (0.72), and glucose
110.19 (26.52) mg/dL.
Only CRP concentrations were associated with the
presence of BMLs (OR = 1.43, 95% CI = 1.09 to 1.87;
Table 1). There were no associations between GSP or
glucose levels and the presence of BMLs.
We found a statistical interaction between BMI and
CRP when assessing effusion: among adults with a BMI
<25 kg/m2, there was a trend for a positive association
between CRP and knee effusion (OR = 1.40, 95% CI 1.00
to 1.97) but this association was null for overweight or
obese individuals (OR = 0.83, 95% CI = 0.65 to 1.07). We
detected a nonlinear relationship between lnGSP levels
and the presence of baseline effusion: for lnGSP levels
≥5.5cm3, individuals with greater GSP concentrations
were more likely to have baseline effusion (OR = 2.02).
In contrast, for lnGSP levels <5.5cm3, individuals with
lower GSP concentrations were more likely to have effu-
sion (OR = 0.39; see Table 2). Fasting glucose levels were
not significantly associated with the presence of baseline
effusion.
In sensitivity analyses, we found that adjusting for
smoking or limiting the sample to people with no
diabetes had little influence on the estimated odds ratios
(< 10% change in OR). We found no significant interac-
tions with sex.
Discussion
Among adults without knee OA, we found that people
with greater systemic inflammation (CRP concentrations)
were more likely to have a BML. Furthermore, among
individuals with a normal weight, adults with high CRP
Table 1 C-reactive protein is associated with the prevalence of bone marrow lesions (BMLs)
Predictor (continuous) No BML
(n = 287)
Mean (SD)
(Reference)
Prevalent BML
(n = 56)
Mean (SD)
Prevalent BML
Crude OR (95% CI), p-value
(per unit of biomarker concentration)
Prevalent BML
Adjusted OR (95% CI), p-value
(per unit of biomarker concentration)
C-reactive Protein (mg/L) 3.24 (1.22) 3.67 (1.12) 1.36 (1.05, 1.75), 0.02 1.43 (1.09, 1.87), 0.01
Glycated serum protein (log) 5.50 (0.70) 5.43 (0.82) 0.87 (0.58, 1.32), 0.52 0.97 (0.65, 1.46), 0.90
Glucose (mg/dL) per 10 mg/dL 109.3 (27.2) 114.6 (22.2) 1.08 (0.97, 1.20), 0.18 1.07 (0.95, 1.19), 0.28
Adjusted analyses include age, body mass index, sex, and Physical Activity Scale for the Elderly Score. OR odds ratio, 95% CI 95% confidence interval. Bold
represents statistically significant findings (p < 0.05)
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concentrations may be more likely to have knee effusion.
Finally, GSP concentrations had a “U-shaped” relationship
with effusion. These findings highlight the complex rela-
tionships that systemic inflammation and impaired glu-
cose homeostasis may have among knees without OA.
Our results complement a prior study of people with
knee OA in which the authors reported positive associa-
tions between quartiles of CRP and the prevalence and
worsening of knee BMLs over 2 years [28]. We went be-
yond quartile readings and looked at CRP as a continu-
ous variable, finding a linear relationship between CRP
concentrations and BML presence. While Zhu, et al.
[28] collected data from participants with symptomatic
knee OA, our study focused on individuals without knee
OA, but with established risk factors for the disease.
Only one study has looked at the relationship between
glucose and BMLs. Specifically, the authors found a
positive association between glucose levels and incident
BMLs in women but not in men [30]; however, fasting
glucose samples were collected >9 years prior to the ini-
tial MR images that were used for BML measurements.
In contrast, we examined glucose concentrations in
serum collected during the same visit as the MR images.
Additionally, a novel aspect of our study was that we
looked at a more stable metric of glucose homeostasis,
GSP, rather than focusing purely on fasting glucose
levels.
The inclusion of GSP in our analyses proved insightful
as we found associations between GSP levels and the
presence of baseline effusion. Our results complement
our previous study that found a U-shaped correlation
between GSP concentrations and incident knee OA: spe-
cifically, individuals with lnGSP concentrations <5.7 and
individuals with lnGSP concentrations >5.7 were more
likely to develop incident knee OA than those with
lnGSP concentrations closer to 5.7 [32]. This U-shaped
relationship may indicate that there are two clinically
relevant subsets with effusion that warrant more study –
those with low GSP concentrations and others with high
GSP concentrations. Increased formation of advanced
glycation end-products leads to increased collagen
cross-linking, which can make the cartilage more brittle.
This in turn can induce cartilage fragmentation [43],
which could aggravate the synovium causing an increase
in effusion volume [44, 45]. This may help explain the
positive association between high GSP levels and effu-
sion. Alternatively, the presence of knee effusion may
lead to joint symptoms, which leads to a more sedentary
life style and consequently a greater risk for impaired
glucose homeostasis. Future studies should explore the
cause for this association, as well as why low GSP levels
are associated with effusion.
We also observed a trend that CRP had a positive as-
sociation with effusion among individuals with a normal
weight (BMI <25 kg/m2) but not among adults who were
overweight or obese. This may indicate that other factors
besides systemic inflammation contribute to effusion
among individuals who are overweight or obese. The in-
creased joint load in an overweight or obese individual
can cause cartilage damage [46], and cartilage fragments
may aggravate the synovium [41, 45]. It is important to
note that the cross-sectional nature precludes us from
determining if the presence of effusion – or other path-
ologies that contribute to effusion – may contribute to
greater systemic inflammation among normal weight
adults but not among individuals who are overweight
and obese.
There were several potential limitations to our study.
With our limited sample size, we may not have adequate
power to explore more interactions, especially with the
presence of nonlinear relationships. Despite this limita-
tion, we detected nonlinear patterns and interactions
that may be important to future research. It is vital that
future studies anticipate non-linear relationships be-
tween glucose homeostasis and effusion. Secondly, our
study did not consider the association between local in-
flammatory biomarkers and BMLs or effusion. We chose
to focus solely on the whole-body burden of glucose and
inflammatory homeostasis. There are many systemic and
local factors that may contribute to changes in glucose
and inflammatory homeostasis. Hence, we cannot infer
causation; however, despite other possible causes for al-
tered glucose and inflammatory homeostasis, BMLs, and
effusion they are associated. Thirdly, the cross-sectional
Table 2 Glycated serum protein is associated with the prevalence of effusion
Predictor (continuous) No-Little Effusion
(n = 173)
Mean (SD)
(Reference)
Effusion (≥ 7.5 cm3)
(n = 170)
Mean (SD)
Prevalent Effusion
Crude OR (95% CI), p-value
(per unit of biomarker concentration)
Prevalent Effusion
Adjusted OR (95% CI), p-value
(per unit of biomarker concentration)
CRP (mg/L) 3.29 (1.27) 3.34 (1.16) 1.04 (0.87, 1.24), 0.68 1.01 (0.83, 1.22), 0.93
lnGSP <5.5 5.10 (0.29) 4.99 (0.40) 0.36 (0.18, 0.73), 0.004 0.39 (0.18, 0.83), 0.01
lnGSP ≥5.5 6.01 (0.49) 6.29 (0.71) 2.01 (1.22, 3.32), 0.01 2.02 (1.22, 3.34), 0.01
Glucose (mg/dL) per 10 mg/dL 108.7 (27.9) 111.7 (25.1) 1.04 (0.96, 1.13), 0.31 1.03 (0.95, 1.12), 0.48
All analyses were adjusted for age, body mass index, sex, and Physical Activity Scale for the Elderly score. CRP C-reactive Protein, lnGSP glycated serum protein
(log), OR odds ratio, 95% CI 95% confidence interval. Bold represents statistically significant findings (p < 0.05)
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nature precludes us from making any causal inferences
or disentangling whether systemic inflammation or
glucose homeostasis leads the joint to be susceptible to
BMLs or effusion or if the presence of BMLs and
effusion may contribute to changes in systemic
inflammation or glucose homeostasis. Finally, we used a
sample that was enriched to include people who later de-
velop radiographic knee OA and not a population-based
sample, which would enable results that are more
generalizable. Future population-based studies may build
on these findings. Despite these limitations, we found novel
associations and interactions that warrant further study.
Conclusions
We found that systemic inflammation, specifically CRP,
may be associated with BMLs and effusion in normal
weight individuals. Furthermore, glucose homeostasis,
determined using GSP, may be associated with effusion.
Though our results indicate that inflammatory and glu-
cose homeostasis are related to structural features of
OA, it will be valuable to determine whether inflamma-
tory and glucose homeostasis are related to incident
symptomatic OA. Further understanding of these associ-
ations may help us develop strategies to prevent or delay
symptomatic OA or alternatively to prevent an adverse
influence of knee OA on systemic inflammation and im-
paired glucose homeostasis.
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